Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 June 2020Website:
http://www.royaltypharma.comNext earnings report:
06 November 2024Last dividends:
16 August 2024Next dividends:
15 November 2024Price
after hours | Fri, 01 Nov 2024 22:36:51 GMTAnalysts recommendations
Institutional Ownership
RPRX Latest News
Beyond analysts' top -and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day.
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share.
Royalty Pharma (RPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
With their high yields and strong underlying businesses, these stocks are hard to pass up.
At less than 8 times trailing earnings, Western Union looks like a bargain. Royalty Pharma could grow its specialty financing business much faster than its recent valuation suggests.
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes
Vertex franchise poses a significant downside risk. That said, Royalty Pharma has solid execution capabilities and is diversifying earnings with new investments. The company raised its 2024 outlook after three quarters of double-digit growth. A solid team, a balance sheet with M&A maneuvers, and an impressive track record make the company a buy.
Royalty Pharma's stock has underperformed recently, down 7% year to date while the S&P500 has climbed 13%. In the company's latest Q2'24 results, Royalty Pharma reported a 12% increase in portfolio receipts, driven by sales growth from its cystic fibrosis franchise and other drugs. The company has also been active in acquiring new royalties and investing in various therapeutic areas and is on track to exceed deployment targets.
- 1(current)
- 2
What type of business is Royalty Pharma?
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
What sector is Royalty Pharma in?
Royalty Pharma is in the Healthcare sector
What industry is Royalty Pharma in?
Royalty Pharma is in the Biotechnology industry
What country is Royalty Pharma from?
Royalty Pharma is headquartered in United States
When did Royalty Pharma go public?
Royalty Pharma initial public offering (IPO) was on 16 June 2020
What is Royalty Pharma website?
https://www.royaltypharma.com
Is Royalty Pharma in the S&P 500?
No, Royalty Pharma is not included in the S&P 500 index
Is Royalty Pharma in the NASDAQ 100?
No, Royalty Pharma is not included in the NASDAQ 100 index
Is Royalty Pharma in the Dow Jones?
No, Royalty Pharma is not included in the Dow Jones index
When was Royalty Pharma the previous earnings report?
No data
When does Royalty Pharma earnings report?
The next expected earnings date for Royalty Pharma is 06 November 2024